ReviewBioengineering (Basel, Switzerland)2025
Bioprinting and Intellectual Property: Challenges, Opportunities, and the Road Ahead.
Review in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Formal Optimization-Oriented Design Framework for Predictive Extrusion-Based 3D Bioprinting.Biomimetics (Basel, Switzerland) · 2026Article
- Advances in 3D Bioprinting: Materials, Processes, and Emerging Applications.Micromachines · 2026Review
- Engineering Resilience: How Irradiation Strategies Influence 3D-Bioprinted Adipose Stem Cells.Bioengineering (Basel, Switzerland) · 2025Article
- Organ-Specific Strategies in Bioprinting: Addressing Translational Challenges in the Heart, Liver, Kidney, and Pancreas.Journal of functional biomaterials · 2025Review
- Formulation of Recombinant Therapeutic Proteins: Technological Innovation, Regulations, and Evolution Towards Buffer-Free Formulations.Pharmaceutics · 2025Review
- Biomimetic Additive Manufacturing: Engineering Complexity Inspired by Nature's Simplicity.Biomimetics (Basel, Switzerland) · 2025Article
- Tissue Regeneration of Radiation-Induced Skin Damages Using Protein/Polysaccharide-Based Bioengineered Scaffolds and Adipose-Derived Stem Cells: A Review.International journal of molecular sciences · 2025Review
- Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Optimization of LCD-Based 3D Printing for the Development of Clotrimazole-Coated Microneedle Systems.Materials (Basel, Switzerland) · 2025Article
- From Stents to Smart Implants Employing Biomimetic Materials: The Impact of 4D Printing on Modern Healthcare.Biomimetics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioprinting, an innovative combination of biotechnology and additive manufacturing, has emerged as a transformative technology in healthcare, enabling the fabrication of functional tissues, organs, and patient-specific implants. The implementation of the aforementioned, however, introduces unique intellectual property (IP) challenges that extend beyond conventional biotechnology. The study explores three critical areas of concern: IP protection for bioprinting hardware and bioinks, ownership and ethical management of digital files derived from biological data, and the implications of commercializing bioprinted tissues and organs. Employing a multidisciplinary approach, the paper analyzes existing IP frameworks, highlights their limitations when applied to bioprinting, and examines ethical dilemmas, such as ownership of bioprinted human tissues and the commodification of biological innovations. Findings suggest that current IP laws inadequately address the complexities of bioprinting, particularly in managing the intersection of proprietary technologies and ethical considerations. The study underscores the need for adaptive legal and ethical frameworks to balance innovation with equitable access and sustainability. Recommendations include the development of tailored IP policies for bioprinting and enhanced international collaboration to harmonize legal protections across jurisdictions. This work aims to provide a comprehensive foundation for stakeholders to navigate the rapidly evolving landscape of bioprinting IP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.